Introduction {#s1}
============

Major depressive disorder (MDD) is among the most prevalent and disabling mental disorders, one of the leading causes of disability worldwide, and a major contributor to the overall global burden of disease ([@B1]). One of the most prevalent somatic comorbidities of MDD is obesity ([@B2], [@B3]). Several studies have provided evidence for a bidirectional link between depression and obesity in a way that the presence of one is increasing the risk of developing the other ([@B3]--[@B6]). Further, as stated by Milaneschi et al. ([@B3]), there is strong reason to believe that these conditions are interconnected through a vicious, mutually reinforcing cycle of adverse physiological adaptations.

Several factors, such as biological, psychological, and behavior-related ones, may influence this complex association between depression and obesity (e.g., [@B7], [@B9]--[@B12]). Moreover, depression and obesity are two major risk factors of negative health outcomes ([@B10], [@B13], [@B14]).

The inter-individual heterogeneity of depressive symptoms in different patients with MDD grants to a greater variability in its association with obesity. This association seems to be stronger in certain subgroups of patients ([@B3], [@B6], [@B15], [@B16]); for example, the association between depression and obesity is found to be stronger for abdominal obesity, and in some studies and certain populations, it was found to be inverse or even absent ([@B17]--[@B19]). Several (e.g., genetic and inflammatory) factors and mechanisms are being discussed in the international literature to date ([@B3], [@B10], [@B20]--[@B22]). Genetic factors influence likewise depression and obesity, with additive effects explaining the phenotypic variation for both depression and body mass index (BMI) ([@B3], [@B23], [@B24]). To sum up, there is emerging evidence that the relationship between depression and obesity has its origins in partially overlapping genetic bases ([@B3]).

The clinical impression also supports the hypothesis that patients with the same MDD diagnosis may endorse very different symptom patterns depending on their body weight status ([@B3]). For example, obesity seems to be associated with fatigue in the sense of tiredness (lack of drive and sleepiness), which may result from somatic reactions to the condition of obesity, whereas typical depression is associated with inhibition of drive and long sleep latencies ([@B25]--[@B27]).

In the past decades, quite some efforts have been made to determine and establish different depressive symptom patterns or clusters and examine their influence on various health-related outcomes. In most of these studies, depressive symptom patterns or clusters were distinguished as follows: a) two symptom clusters: cognitive-affective (e.g., pessimism, guilt, and self-dislike) and somatic-affective (e.g., insomnia, fatigue, and work difficulty) depressive symptoms ([@B28], [@B29]) or b) three symptom clusters: cognition/mood, anxiety/arousal, and vegetative symptoms (or sleep) ([@B30], [@B31]). However, other distinctions were also proposed, such as a differentiation between atypical and melancholic depressive subtypes ([@B32]--[@B34]).

As mentioned above, a growing body of evidence indicates that abdominal obesity is a more important risk factor of MDD than general obesity ([@B35]). It seems to be the key mediator in the relationship between obesity and depression ([@B36]). Results indicate a positive association between abdominal fat distribution \[measured by waist-to-hip ratio (WHR)\] and prevalence of depression, and further that abdominal obesity is a risk factor of depression independently of general obesity (measured by BMI). Nevertheless, some epidemiological studies report no association between unfavorable waist circumference and mental disorders (in particular depression) ([@B17]). Considering these differential associations, it seems beneficial to take into account different measures for body weight status, not only BMI ([@B37]).

However, only a few studies have addressed anthropometric measures in relation to different depressive symptoms so far ([@B38]), with equivocal results: one study reported that BMI was associated with both cognitive-affective and somatic-affective depressive symptom patterns of the Beck Depression Inventory I (BDI-I), whereas waist circumference and WHR were only associated with somatic-affective, but not cognitive-affective symptoms ([@B39]). Another study reported as a secondary result that BMI at baseline was significantly correlated with improvement in neurovegetative and cognitive symptoms of depression ([@B2]). It has also been shown in a population-based study that only the somatic, not the cognitive-affective, symptoms of depression are positively associated with anthropometric measures of obesity ([@B35]).

The aim of this study is the investigation of self-rated depressive symptoms (assessed with the Inventory of Depressive Symptomatology Self Report, IDS-SR30 clusters: mood symptoms, somatic/vegetative symptoms, and cognitive symptoms) in relation to body weight status in persons with overweight and obesity and normal-weight individuals reporting subthreshold depressive symptoms. Different measures for body weight status (WHR and BMI) will be examined.

Methods {#s2}
=======

Study Design {#s2_1}
------------

This publication includes baseline data from two large European multicenter studies: the MooDFOOD Trial ("Multi-country cOllaborative project on the role of Diet, Food-related behavior, and Obesity in the prevention of Depression") and the NESDA Study ("The Netherlands Study of Depression and Anxiety"), respectively.

The MooDFOOD Trial for the prevention of depression in individuals with overweight and obesity reporting subclinical depressive symptoms is a 2 × 2 factorial randomized controlled trial. It was carried out between July 2015 and October 2017 in four European countries (Germany, Spain, United Kingdom, and the Netherlands). For full details of trial design and protocol see Roca et al. ([@B40]), and for primary outcome results see Bot et al. ([@B41]). The trial was approved by the Human Research Ethics Boards of all four study sites. All participants provided written informed consent prior to participation.

The NESDA Study is an ongoing multicenter, longitudinal, naturalistic cohort study examining the 9-year course and consequences of depressive and anxiety disorders (for details of study design and protocol, see [@B42]). Baseline assessments of NESDA took place between 2004 and 2007. The study includes persons with a current or lifetime diagnosis of depression and/or anxiety disorder, persons being at risk for these disorders because of a family history or subthreshold depressive or anxiety symptoms, and healthy controls, respectively. Ethics approval was provided by the local review boards of all study sites and written informed consent was obtained from all participants prior to participation.

For this publication, baseline data from both the MooDFOOD Trial (total *N* = 1,025) and the NESDA Study (total *N* = 2,981) were combined to provide a sample with a wide range of body weight status. To this end, only the data of normal-weight participants from the NESDA Study were used to provide a matching sample to the MooDFOOD data of individuals with overweight and obesity (see below for details on propensity score matching procedure).

Recruitment and Eligibility Criteria {#s2_2}
------------------------------------

Participants for the MooDFOOD Trial were recruited from the general population *via* websites, advertisements, and press releases as well as *via* other studies conducted at the study sites and mailings to registered subjects in the general practice setting or in city registers. Inclusion criteria were age 18-75 years, BMI in the range of 25--40 kg/m^2^, and subclinical depressive symptoms as operationalized by a Patient Health Questionnaire (PHQ-9) score of ≥5 ([@B43]). Main exclusion criteria included a current (including the past 6 months) MDD episode according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV; ([@B44]), as assessed by the Mini-International Neuropsychiatric Interview (MINI 5.0; [@B45]), current use of antidepressants, current eating disorder or a severe life-threatening physical disease (e.g., cancer), and a history of psychosis, bipolar disorder, substance dependence, or another severe psychiatric disorder ([@B40]). All eligible participants were invited for a baseline interview, physical measurements, and blood sampling conducted by trained research assistants/nurses and the completion of self-report questionnaires. Follow-up assessments took place at 3, 6, and 12 months.

Participants for the NESDA Study were recruited from community samples, primary care practices, and mental health organizations, in order to represent diverse settings and developmental stages of psychopathology. Participants aged 18--65 years were included in the study. Further inclusion criteria were a current (including the past 6 months) or lifetime diagnosis of depression (minor or major depression, dysthymia) or anxiety disorders according to the DSM-IV, as assessed by the Composite International Diagnostic Interview (CIDI, WHO version 2.1; [@B46]). In addition, persons with a family history of depression or anxiety disorders and with subclinical depressive or anxiety symptoms were included, as well as healthy controls without any depressive or anxiety symptoms. Main exclusion criteria were psychosis, obsessive compulsive disorder, bipolar disorder, severe addiction, and a history of stroke ([@B42]). Eligible participants were invited for a baseline assessment including clinical interviews and physical measurements conducted by trained research assistants and the completion of self-report questionnaires. Follow-up assessments took place every 2 years after baseline and are currently ongoing.

Propensity Score Matching and Study Sample {#s2_3}
------------------------------------------

The baseline data of the MooDFOOD Trial included *N* = 1,025 participants in total. To match these data with the data of the NESDA Study, *n* = 35 participants had to be excluded from the dataset \[*n* = 14 with normal body weight and *n* = 21 with history of stroke (exclusion criterion in the NESDA sample)\], resulting in a dataset of *n* = 990 participants from the MooDFOOD Trial.

Baseline data of the NESDA Study included *N* = 2,981 participants. Of these, *n* = 2,544 had to be excluded during data preparation for the following reasons: *n* = 1,481 not normal body weight, *n* = 540 with current MDD (as this was an exclusion criterion in MooDFOOD), *n* = 113 with antidepressant medication, *n* = 94 with alcohol dependence, and *n* = 316 with anxiety disorders. Thus, the final selected sample out of the NESDA Study comprised *n* = 437.

To obtain a final sample with a wide range of body weight status, including persons with overweight and obesity from the MooDFOOD Trial as well as normal-weight persons from the NESDA Study, propensity score matching was performed ([@B47]). Based on their propensity scores calculated by logistic regression (nearest neighbor matching algorithm, caliper 0.2), samples were matched according to sex, age, and distribution of IDS scores. The final matched sample comprised *n* = 504 participants (*n* = 252 from the MooDFOOD Trial and *n* = 252 from the NESDA Study).

Measures {#s2_4}
--------

*Depressive Symptoms*. In both the MooDFOOD Trial and the NESDA Study, the 30-item Inventory of Depressive Symptomatology Self-Report (IDS-SR30; [@B30], [@B48]) was administered to assess depressive symptoms (0 = *no problems* to 3 = *severe problems*). The two separate items on weight loss and weight gain were recoded into a single variable. The two items on increased and decreased appetite, respectively, were recoded similarly, resulting in a total of 28 items for the IDS ([@B9], [@B31]). A total sum score was calculated (range, 0--84), with higher scores indicating higher levels of depressive symptomatology. In accordance with previous studies, individual symptoms were categorized into three depressive symptom clusters (deductively defined): mood symptoms, cognitive symptoms, and somatic/vegetative symptoms ([@B9], [@B49], [@B50]). A sum score was calculated for each cluster (mood symptoms: 10 items, range 0--30; cognitive symptoms: 4 items, range 0--12; somatic/vegetative symptoms: 14 items, range 0--42; see [**Supplementary Table**](#SM2){ref-type="supplementary-material"}).

*Body Weight Status*. Body weight, height, and waist and hip circumference were measured objectively according to written, standardized protocols (identical measurement in both subsamples). BMI (in kilograms per square meter) and WHR (waist circumference divided by hip circumference) were calculated.

*Presence of Lifetime MDD*. The presence of a lifetime diagnosis of MDD according to the DSM-IV ([@B44]) was assessed in all study participants using clinical interviews, specifically the MINI 5.0 ([@B45]) in the MooDFOOD Trial and the CIDI \[WHO version 2.1 ([@B46])\] in the NESDA Study.

*Demographic Variables*. Sex and age were assessed in the baseline interview in both, MooDFOOD and NESDA.

All applied interview and questionnaire instruments demonstrated good reliability and validity ([@B51]--[@B53]). The IDS showed good internal consistency with Cronbach's *α* = .80.

Statistical Analysis {#s2_5}
--------------------

Statistical analyses were performed using IBM SPSS Statistics version 24.0. Differences in sample characteristics between participants from MooDFOOD and NESDA, respectively, were examined using general linear model analyses for continuous variables (age, BMI, WHR, and IDS scores) and *χ* ^2^ tests for categorical variables (sex and prevalence of lifetime MDD). To analyze the relationship between depressive symptoms and body weight status, two separate multiple linear regression analyses were computed with the anthropometric measure (BMI and WHR) as the continuous dependent variable and the depressive symptoms (clusters: mood symptoms, cognitive symptoms, and somatic/vegetative symptoms) and sociodemographic variables (sex and age) as the independent variables. Tests for assumption of collinearity of the independent variables showed that multicollinearity was not a concern. The independent variables were entered into the models simultaneously. Effect size of prediction was evaluated according to Cohen ([@B54]), *R* ^2^: small, .01; medium, .09; large, .25. A two-tailed *α* = 0.05 was applied to all statistical testing.

Results {#s3}
=======

Sample Characteristics {#s3_1}
----------------------

Participants from MooDFOOD (*n* = 252) and NESDA (*n* = 252), respectively, did not differ regarding sex, age, prevalence of lifetime MDD, IDS total scores, and IDS symptom clusters (all *p* \> .05; see [**Table 1**](#T1){ref-type="table"}). As expected, participants from MooDFOOD showed significantly higher BMI and WHR than participants from NESDA (all *p* \< .05).

###### 

Sample characteristics for the MooDFOOD and NESDA subsamples and the total matched sample.

                                 Total sample (n = 504)   MooDFOOD (n = 252)   NESDA (n = 252)   Test                p
  ------------------------------ ------------------------ -------------------- ----------------- ------------------- ------------
  Sex (*N* female, %)            368 (73.0)               185 (73.4)           183 (72.6)        *χ* ^2^(1) = 0.04   .841
  Lifetime MDD (*N*, %)          150 (29.9)               76 (30.4)            74 (29.4)         *χ* ^2^(1) = 0.06   .800
                                 *M* (SD)                 *M* (SD)             *M* (SD)          *F*(1, 502)         
  Age                            41.93 (13.61)            42.52 (12.85)        41.35 (14.33)     0.93                .335
  Body mass index (kg/m^2^)      26.62 (5.33)             31.04 (3.86)         22.19 (1.66)      1,117.92            **\<.001**
  Waist-to-hip ratio             0.86 (0.09)              0.89 (0.09)          0.82 (0.07)       92.42               **\<.001**
  IDS total score                13.47 (7.52)             13.69 (7.52)         13.25 (7.53)      0.44                .508
   Mood symptoms                 4.11 (3.41)              4.13 (3.41)          4.10 (3.41)       0.01                .927
   Cognitive symptoms            1.66 (1.67)              1.64 (1.57)          1.69 (1.78)       0.12                .730
   Somatic/vegetative symptoms   7.67 (4.03)              7.92 (4.02)          7.41 (4.03)       2.07                .151

Using propensity score matching, samples from the MooDFOOD Trial and the NESDA Study were matched according to sex, age, and distribution of IDS sum scores. Tests for group differences refer to differences between the MooDFOOD and NESDA subsamples, respectively.

M, mean; SD, standard deviation; MDD, major depressive disorder; IDS, Inventory of Depressive Symptomatology Self-Report.

Bold type p \< .05.

The total sample comprised *n* = 504 individuals (73.0% women) with a mean age of *M* = 41.93 years (SD = 13.61), a mean BMI of *M* = 26.62 kg/m^2^ (SD = 5.33, range = 18.56--42.10 kg/m^2^), and a mean WHR of *M* = 0.86 (SD = 0.09, range = 0.66--1.12; see [**Table 1**](#T1){ref-type="table"}). Criteria for a lifetime MDD diagnosis were met by *n* = 150 (29.9%). Based on IDS cutoff scores for clinical severity of depressive symptoms, no values fell in the categories of severe or very severe depressive symptoms. Of the total sample, *n* = 292 (58%) participants had no or low severity of depressive symptoms, *n* = 175 (35%) had mild severity, and *n* = 37 (7%) displayed moderately severe depressive symptoms, respectively.

Multiple Linear Regression Analyses {#s3_2}
-----------------------------------

Two separate multiple linear regression analyses were calculated to predict BMI and WHR, respectively, based on sociodemographic variables and depressive symptom clusters. The first analysis with BMI as the outcome variable did not yield a significant regression equation: *F*(5, 498) = 2.01, *p* = .076, *R* ^2^ = .02, adjusted *R* ^2^ = .01; see [**Table 2**](#T2){ref-type="table"} and [**Supplementary Figure**](#SM1){ref-type="supplementary-material"}). While sociodemographic variables as well as mood and cognitive symptoms were not significantly associated with BMI (all *p* \> .05), results showed that the somatic/vegetative symptom cluster had a significant effect (*p* = .013). More somatic/vegetative symptoms were associated with a higher BMI.

###### 

Linear regression analyses of depressive symptom clusters and weight status (*n* = 504; matched sample from MooDFOOD and NESDA)

                                 Total sample (*N* = 504)                  
  ------------------------------ -------------------------- ------- ------ ------------
  Body mass index                                                          
   Sex                           0.04                       -0.46   0.54   .369
   Age                           0.07                       0.03    0.02   .117
   Mood symptoms                 -0.03                      -0.04   0.10   .650
   Cognitive symptoms            -0.04                      -0.13   0.18   .476
   Somatic/vegetative symptoms   0.13                       0.18    0.07   **.013**
  Waist-to-hip ratio                                                       
   Sex                           -0.50                      -0.10   0.01   **\<.001**
   Age                           0.30                       0.00    0.00   **\<.001**
   Mood symptoms                 -0.05                      0.00    0.00   .293
   Cognitive symptoms            -0.02                      0.00    0.00   .704
   Somatic/vegetative symptoms   0.12                       0.00    0.00   **.006**

Bold type p \< .05.

Results of the second analysis with WHR as the outcome variable indicated that there was a collective significant association of the independent variables: *F*(5, 496) = 50.11, *p* \< .001, *R* ^2^ = .34, adjusted *R* ^2^ = .33; see [**Table 2**](#T2){ref-type="table"} and [**Supplementary Figure**](#SM1){ref-type="supplementary-material"}). Examination of the individual variables showed that sex, age, and somatic/vegetative symptoms yielded significant effects in the model (all *p* \< .01). Being male, older age, and more somatic/vegetative symptoms were associated with a higher WHR.

In both models, standardized regression coefficients (beta) for somatic/vegetative symptoms were larger than those for mood and cognitive symptoms, respectively (see [**Table 2**](#T2){ref-type="table"}).

Discussion {#s4}
==========

The aim of this study was to investigate the relationship between depressive symptom clusters (mood symptoms, somatic/vegetative symptoms, and cognitive symptoms) in relation to body weight status, measured by BMI and WHR, in individuals with subthreshold depressive symptoms. Using a sample comprising two large European multicenter studies, the current study is, to our knowledge, the first to address this question.

Results showed that the significant regression model with WHR as the outcome variable yielded a reasonably high model fit, explaining 33% of the variance. It revealed that being male, being of older age, and reporting more depressive symptoms of the somatic/vegetative symptom cluster were significantly associated with higher WHR. Mood and cognitive symptoms did not show any significant contribution. To sum up, age, sex, and somatic/vegetative symptoms, but not mood or cognitive symptoms, were significantly associated with WHR. This finding is in line with previous research indicating that the somatic/affective symptoms of depression rather than the cognitive/affective ones are consistently related to anthropometric measures of obesity ([@B35]).

The regression model with BMI as the outcome variable did not reach statistical significance overall, meaning that the majority of the variables did not contribute to BMI. Nevertheless, the factor somatic/vegetative symptoms yielded a significant effect, which points towards the fact that this factor is associated with BMI, but the others do not.

Overall, the results of this study provide further evidence that somatic/vegetative symptoms rather than mood/cognitive symptoms of depression are associated with WHR, and potentially of BMI as well. Somatic/vegetative symptoms include pain, change in appetite and body weight, gastrointestinal, and several arousal-related symptoms (sleep and energy level) (see [**Supplementary Table**](#SM2){ref-type="supplementary-material"}). The latter are depressive symptoms that are mainly manifested in the somatic area, which might overlap or coincide with complaints and symptoms accompanying or resulting from overweight or obesity and co-occurring somatic conditions.

Moreover and also in line with the international literature, the results suggest that future research should take different body weight status measures (such as WHR) for obesity into account, not only BMI, as other measure index abdominal obesity, which is proposed to be the key factor in the obesity--depression relationship ([@B35], [@B36]).

The current study has important strengths. It included a large, multicenter, multi-country, and propensity score-matched sample and further used standardized assessment instruments. However, there are also some limitations. First, the results might not be generalizable to the full spectrum of depressive disorders and specifically to individuals currently suffering from MDD, as the study population comprised individuals with subthreshold symptoms of depression, but indeed 30% with a lifetime MDD diagnosis. Nevertheless, the full range of body weight state was included in the analysis. Due to the cross-sectional design, causal inferences are not possible and not all potentially relevant control variables (e.g. physical activity) could be included into the analysis. The depressive symptoms being analyzed in this study are administered *via* self-report measures, which might be biased by social desirability and other factors. Also, self-report instruments and clinician-rated scales differ regarding content and weighting of different symptom dimensions. Also, the potential role of certain medical comorbidities regarding this association is not addressed within this analysis.

In conclusion, the present study provides further evidence that there is heterogeneity in depressive symptoms in relation to body weight status, especially as assessed by the WHR. Future studies could investigate the longitudinal course of different depressive symptom clusters and their differential associations with body weight status in the long term. Treatment strategies of both depression and obesity should take the present results into account, e.g., by adapting and targeting interventions to the presented (heterogeneous) symptoms displayed by the individual patient.
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